Posted by Michael Wonder on 14 May 2019
PHARMAC publishes list of applications to be considered by PTAC later this month
14 May 2019 - The list includes a number of medicines for patients with breast cancer.
Interestingly, the list includes CDK4/6 inhibitors; one suspects that PTAC will consider the listing of palbociclib and ribociclib succinate (and perhaps abemaciclib).
This is typical PHARMAC conduct; publish a list that is not clear (non-transparent) and stall decision making on a new first-in-class medicine until the second and perhaps third medicine in the class become available such that it can trade off one supplier against the other.
